关于先锋

Company Profile

Research cooperation

Research trends

Research strength

Bioequivalence Study of Fenofibrate Capsules in Human

Release time:

2023-07-12

Indications:

For adult use It is used for the treatment of hypercholesterolemia (type IIa), endogenous hypertriglyceridemia, simple type (type IV) and mixed type (type IIb and type III) in adults whose diet control therapy is not satisfactory. Especially when the blood cholesterol continues to rise after diet control, or when there are other concurrent risk factors. You should continue to control your diet while taking the medicine. At present, there is no long-term controlled clinical study to prove the effectiveness of fenofibrate in the primary and secondary prevention of atherosclerotic complications. Fenofibrate has not been shown to reduce coronary morbidity and mortality in patients with type 2 diabetes.

Test group:

1

End point indicators:

1

Number of subjects:

Serial number

Enterprise

Number of subjects

1

Anhui Pioneer Pharmaceutical Co., Ltd.

84 cases

2

Chenxin Pharmaceutical Co., Ltd.

58 cases

3

Jiangsu Biyi Biotechnology Co., Ltd.

80 cases
Back →

Related news

2023-07-25

Generic drug development field

2023-07-12

Bioequivalence Study of Oseltamivir Phosphate Capsules in Human

2023-07-12

Study on Bioequivalence of Lamotrigine Dispersible Tablets in Human

2023-07-12

Bioequivalence Study of Sildenafil Citrate Orally Disintegrating Tablets in Human

2023-07-12

Bioequivalence Study of Fenofibrate Capsules in Human